STUDY OF MOLECULAR MECHANISMS REGULATING NORMAL AND MALIGNANT HEMATOPOIESIS (AML)
- Target discovery
- AML
- Targeted therapy
- Basic research (TRL 1-3)
Studies of transcription regulation in normal and tumor hematopoietic cells.
Knowledge of the transcription factors involved in the regulation of gene expression and epigenetics in normal and tumor hematopoietic cells. The perspectives are to identify specific markers of leukemia cells that could be targeted with minimal consequences on normal hematopoietic cells.
Description
Scope of research activities
Basic research in normal and tumor hematopoietic cells.
Conducting studies
Steps:
- Analysis of innovative product development strategy
- Study design
- Drafting of study plans
- Organization, implementation and conduct of studies
- Analysis and communication of results
Research infrastructure
Experimental and analytical platforms:
- Preclinical research platform (hosting preclinical cancer models; preclinical evaluation of models and therapies phenotyping, experimental pathology)
- Integrated biology platform (genomics, proteomics and metabolomics)
- Imaging and cytometry platform
- Individual CRISPR/Cas9 screening or screens
- Bioinformatics (transcriptome, single cell transcriptome, chromatin accessibility, activity inference)
Models:
- AML PDX models
- Transgenic mouse models: doxycycline-inducible model of ETO2-GLIS2 fusion expression in a C57BL/6 background
- Leukemia cell lines: MO7e, CMS, CMK, HEL, lines with oncogenes expressing a fluorescent tag (GFP or Scarlet) or a degron
- Human induced pluripotent stem (iPSC) cell lines expressing oncogenes
Technical personnel:
- Pre-clinical experimentation technician/engineer
Specifications
Studies
Analysis of epigenetic regulators:
- Transcriptome, single cell transcriptome
- ATAC-seq
- ChIP-seq (Transcription factors, Histone marks)
Terms
OPALE entity
Gustave Roussy (UMR-1170)
Team leader
Contact
Dr. Sandrine PalcyBusiness Development Director